Binge Eating Liraglutide Intervention

NCT03279731 on ClinicalTrials.gov · last registry update 2020-11-24

Stopped early, having planned 36 participants. The sponsor logged completion for 30 September 2019. Primary outcome, as filed: Binge Episodes.

Status: TERMINATED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Kelly Allison
Sponsor type: Other
Enrollment: 36
Started: 2017-09-29
Primary completion: 2019-09-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Binge Episodes

Conditions studied

Binge-Eating Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.